
RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban
Summary: There doesn't seem to be new safety or efficacy information, but Kennedy touts them anyway. Background Context Market participants continue to weigh supply dynamics, regulatory signals, and enterprise adoption when assessing near-term outcomes.
Kenji Sato · April 16, 2026









